Efficacy and safety of etanercept in chronic immune-mediated disease. - Wikidata - awgldk - TriplyDB

Efficacy and safety of etanercept in chronic immune-mediated disease.

Efficacy and safety of etanercept in chronic immune-mediated disease.

http://www.wikidata.org/entity/Q38198080

about

Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.Vaccine-preventable infections in Systemic Lupus Erythematosus.Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Infection risk associated with anti-TNF-α agents: a review.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis.Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil.The antifibrogenic effect of etanercept on development of liver cirrhosis induced by thioacetamide in rats.Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.

P2860

Q33804799-23097591-EE25-4974-A359-AD3A14D413F4 Q37135056-98F2B505-47DB-4BE6-BBDE-AB0EF9886200 Q38258624-8936D6EB-BEF6-40C8-86FF-FDF9FDCFA7E8 Q38335718-DB4D5450-FF40-42E9-ADFE-7CE82A88FDAB Q38631012-330A1F52-7B05-4571-A7EE-2F7882250F66 Q40081220-61474B06-35D3-4688-B9E8-ED70DDF4A641 Q40166046-78208F8E-DD38-4A5E-BDE1-0FD2C8E1695C Q44365951-077EBB4E-2823-42CA-B85E-2E03DB17A9F3 Q46407865-0552C177-DD93-4AEA-A98A-32AE091FD7F6 Q47546977-ED7D88ED-81FD-4D29-A493-4D25E5F4FB67 Q48020447-92931863-0468-4FC0-89A3-8C3D81588179 Q50936406-FD48D74B-F090-431E-B673-3C2E9AEA0C7D

P2860

Efficacy and safety of etanercept in chronic immune-mediated disease.

http://www.wikidata.org/entity/Q38198080

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Efficacy and safety of etanercept in chronic immune-mediated disease.

@en

type

label

Efficacy and safety of etanercept in chronic immune-mediated disease.

@en

prefLabel

Efficacy and safety of etanercept in chronic immune-mediated disease.

@en

P1433

Q38198080-08A29461-F5DC-4DDA-8300-404B51858E49

P1476

Q38198080-7DD19D4C-D691-4790-827D-E698F1A5C9E2

P2093

Q38198080-3383E554-B4C1-4B5E-B45E-C76697392939

Q38198080-7C476B43-2868-4713-8D74-893D556FF300

Q38198080-86318877-B166-4B12-BCE0-D3F4247C69FA

Q38198080-97565CDC-FE7B-44E7-960D-7ED79D5F60FD

Q38198080-CD18711C-3D35-4697-B86D-1474C69100C5

Q38198080-E91B2A0A-4DC6-4D6E-8E54-FC1FFA31A23E

P2860

Q38198080-01409E23-8F92-492F-8458-DF85115C0ABA

Q38198080-036CAE66-F1D2-48A1-8A73-1480431F3209

Q38198080-09CB459F-8A6C-4DF6-83C7-370D721D7998

Q38198080-0D7BFE4B-F2C9-4CE6-A8F8-B5460B8AE575

Q38198080-0F54F3A5-4791-4075-8329-D39827FE39A8

Q38198080-1F317FBD-2CBB-4E34-ADC1-AD3BD0D775F1

Q38198080-20DF9A3E-FA77-465F-B1DC-23CBE82A867A

Q38198080-229C2579-B66C-4A31-98A2-798557055AF9

Q38198080-27702DF0-642F-48F9-A77F-43C0DB84E15C

Q38198080-2CF6D734-EF10-4E89-B457-A7BC9671237F

P304

Q38198080-0824C5F1-B236-46C8-81F5-66BF4D85F315

P31

Q38198080-D0473663-69D0-4B7A-8CB3-5336CC69E151

P356

Q38198080-94F6316C-1B16-4BDC-AF50-91E14C6DB2BD

P407

Q38198080-7643B528-EA64-4C85-97DA-1E9C02677326

P433

Q38198080-01B9186D-D8C2-49CB-944D-A4FFA9764565

P478

Q38198080-FFB4B85A-4464-4C05-B367-9A26AAE01CAE

P577

Q38198080-EE750E1E-2F2E-4248-B509-9A510A0BF0CD

P698

Q38198080-4F570F54-06AB-4FBB-946C-11273C4A3743

P356

14740338.2014.899579

P1433

Expert Opinion on Drug Safety

P1476

Efficacy and safety of etanercept in chronic immune-mediated disease.

@en

P2093

Andrea Guastalla

http://www.w3.org/2001/XMLSchema#string

Francesca Spanò

http://www.w3.org/2001/XMLSchema#string

Francesco Puppo

http://www.w3.org/2001/XMLSchema#string

Giuseppe Murdaca

http://www.w3.org/2001/XMLSchema#string

Miriam Contatore

http://www.w3.org/2001/XMLSchema#string

Ottavia Magnani

http://www.w3.org/2001/XMLSchema#string

P2860

Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

Behçet's disease.

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Antibody therapy for rheumatoid arthritis.

Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Guideline for anti-TNF-alpha therapy in psoriatic arthritis.

Anti-cytokine therapy in systemic lupus erythematosus.

P304

649-661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2014.899579

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24654562

http://www.w3.org/2001/XMLSchema#string